甲状旁腺功能减退

Khan AA, Bilezikian JP, Brandi ML, et al. Evaluation and management of hypoparathyroidism summary statement and guidelines from the Second International Workshop. J Bone Miner Res. 2022 Dec;37(12):2568-85.全文  摘要

Mannstadt M, Cianferotti L, Gafni RI, et al. Hypoparathyroidism: genetics and diagnosis. J Bone Miner Res. 2022 Dec;37(12):2615-29.全文  摘要

Orloff LA, Wiseman SM, Bernet VJ, et al. American Thyroid Association statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults. Thyroid. 2018 Jul;28(7):830-41.全文  摘要

Gafni RI, Collins MT. Hypoparathyroidism. N Engl J Med. 2019 May 2;380(18):1738-47. 摘要

1. Khan AA, Bilezikian JP, Brandi ML, et al. Evaluation and management of hypoparathyroidism summary statement and guidelines from the Second International Workshop. J Bone Miner Res. 2022 Dec;37(12):2568-85.全文  摘要

2. Patel KN, Yip L, Lubitz CC, et al. The American Association of Endocrine Surgeons guidelines for the definitive surgical management of thyroid disease in adults. Ann Surg. 2020 Mar;271(3):e21-93. 摘要

3. Powers J, Joy K, Ruscio A, et al. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013 Dec;28(12):2570-6.全文  摘要

4. Hauch A, Al-Qurayshi Z, Randolph G, et al. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol. 2014 Nov;21(12):3844-52. 摘要

5. Bjornsdottir S, Ing S, Mitchell DM, et al. Epidemiology and financial burden of adult chronic hypoparathyroidism. J Bone Miner Res. 2022 Dec;37(12):2602-14.全文  摘要

6. Underbjerg L, Sikjaer T, Mosekilde L, et al. The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res. 2015 Sep;30(9):1738-44.全文  摘要

7. Mannstadt M, Cianferotti L, Gafni RI, et al. Hypoparathyroidism: genetics and diagnosis. J Bone Miner Res. 2022 Dec;37(12):2615-29.全文  摘要

8. McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore). 2011 Jan;90(1):1-18. 摘要

9. Hacıhamdioğlu B, Hacıhamdioğlu D, Delil K. 22q11 deletion syndrome: current perspective. Appl Clin Genet. 2015 May 18;8:123-32.全文  摘要

10. Nesbit MA, Hannan FM, Howles SA, et al. Mutations affecting G-protein subunit alpha11 in hypercalcemia and hypocalcemia. N Engl J Med. 2013 Jun 27;368(26):2476-86.全文  摘要

11. Hannan FM, Thakker RV. Calcium-sensing receptor (CaSR) mutations and disorders of calcium, electrolyte and water metabolism. Best Pract Res Clin Endocrinol Metab. 2013 Jun;27(3):359-71. 摘要

12. Betterle C, Garelli S, Presotto F. Diagnosis and classification of autoimmune parathyroid disease. Autoimmun Rev. 2014 Apr-May;13(4-5):417-22. 摘要

13. Unger S, Górna MW, Le Béchec A, et al. FAM111A mutations result in hypoparathyroidism and impaired skeletal development. Am J Hum Genet. 2013 Jun 6;92(6):990-5.全文  摘要

14. William JH, Danziger J. Proton-pump inhibitor-induced hypomagnesemia: current research and proposed mechanisms. World J Nephrol. 2016 Mar 6;5(2):152-7.全文  摘要

15. Viering DH, de Baaij JH, Walsh SB, et al. Genetic causes of hypomagnesemia, a clinical overview. Pediatr Nephrol. 2017 Jul;32(7):1123-35. 摘要

16. Wolf MT. Inherited and acquired disorders of magnesium homeostasis. Curr Opin Pediatr. 2017 Apr;29(2):187-98.全文  摘要

17. Agus ZS. Mechanisms and causes of hypomagnesemia. Curr Opin Nephrol Hypertens. 2016 Jul;25(4):301-7. 摘要

18. Lo JC, Loh KC, Rubin AL, et al. Riedel's thyroiditis presenting with hypothyroidism and hypoparathyroidism: dramatic response to glucocorticoid and thyroxine therapy. Clin Endocrinol (Oxf). 1998 Jun;48(6):815-8. 摘要

19. Fatourechi MM, Hay ID, McIver B, et al. Invasive fibrous thyroiditis (Riedel thyroiditis): the Mayo Clinic experience, 1976-2008. Thyroid. 2011 Jul;21(7):765-72. 摘要

20. Pasieka JL, Wentworth K, Yeo CT, et al. Etiology and pathophysiology of hypoparathyroidism: a narrative review. J Bone Miner Res. 2022 Dec;37(12):2586-601.全文  摘要

21. Bergenfelz A, Nordenström E, Almquist M. Morbidity in patients with permanent hypoparathyroidism after total thyroidectomy. Surgery. 2020 Jan;167(1):124-28. 摘要

22. Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 2016 Oct 1;151(10):959-68.全文  摘要

23. Hopkins B, Steward D. Outpatient thyroid surgery and the advances making it possible. Curr Opin Otolaryngol Head Neck Surg. 2009 Apr;17(2):95-9. 摘要

24. Edafe O, Mech CE, Balasubramanian SP. Calcium, vitamin D or recombinant parathyroid hormone for managing post-thyroidectomy hypoparathyroidism. Cochrane Database Syst Rev. 2019 May 22;(5):CD012845.全文  摘要

25. Orloff LA, Wiseman SM, Bernet VJ, et al. American Thyroid Association statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults. Thyroid. 2018 Jul;28(7):830-41.全文  摘要

26. Solórzano CC, Thomas G, Berber E, et al. Current state of intraoperative use of near infrared fluorescence for parathyroid identification and preservation. Surgery. 2021 Apr;169(4):868-78.全文  摘要

27. Gafni RI, Collins MT. Hypoparathyroidism. N Engl J Med. 2019 May 2;380(18):1738-47. 摘要

28. Dickerson RN, Alexander KH, Minard G, et al. Accuracy of methods to estimate ionized and "corrected" serum calcium concentrations in critically ill multiple trauma patients receiving specialized nutrition support. JPEN J Parenter Enteral Nutr. 2004 May-Jun;28(3):133-41. 摘要

29. Smit MA, van Kinschot CMJ, van der Linden J, et al. Clinical guidelines and PTH measurement: does assay generation matter? Endocr Rev. 2019 Dec 1;40(6):1468-80.全文  摘要

30. Chang WT, Radin B, McCurdy MT. Calcium, magnesium, and phosphate abnormalities in the emergency department. Emerg Med Clin North Am. 2014 May;32(2):349-66. 摘要

31. Bilezikian JP, Brandi ML, Cusano NE, et al. Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab. 2016 Jun;101(6):2313-24.全文  摘要

32. Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013 Dec;1(4):275-83. 摘要

33. Watts NB, Bilezikian JP, Bone HG, et al. Long-term safety and efficacy of recombinant human parathyroid hormone (1-84) in adults with chronic hypoparathyroidism. J Endocr Soc. 2023 Mar 6;7(5):bvad043.全文  摘要

34. Mannstadt M, Clarke BL, Bilezikian JP, et al. Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism. J Clin Endocrinol Metab. 2019 Nov 1;104(11):5136-47.全文  摘要

35. Tay YD, Tabacco G, Cusano NE, et al. Therapy of hypoparathyroidism with rhPTH(1-84): a prospective, 8-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2019 Nov 1;104(11):5601-10.全文  摘要

36. Winer KK, Yanovski JA, Sarani B, et al. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998 Oct;83(10):3480-6.全文  摘要

37. Marcucci G, Masi L, Cianferotti L, et al. Chronic hypoparathyroidism and treatment with teriparatide. Endocrine. 2021 Apr;72(1):249-59.全文  摘要

38. Ish-Shalom S, Caraco Y, Khazen NS, et al. Safety and efficacy of oral human parathyroid hormone (1-34) in hypoparathyroidism: an open-label study. J Bone Miner Res. 2021 Jun;36(6):1060-8.全文  摘要

39. Bilezikian JP, Khan AA, Silverberg SJ, et al. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Miner Res. 2022 Nov;37(11):2293-2314.全文  摘要